125 related articles for article (PubMed ID: 16541771)
21. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
Tay MH; Kaufman DS; Regan MM; Leibowitz SB; George DJ; Febbo PG; Manola J; Smith MR; Kaplan ID; Kantoff PW; Oh WK
Ann Oncol; 2004 Jun; 15(6):974-8. PubMed ID: 15151957
[TBL] [Abstract][Full Text] [Related]
22. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
23. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Doyle-Lindrud S
Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
[TBL] [Abstract][Full Text] [Related]
24. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
25. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
26. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
27. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
Mizusawa H; Kontani K; Okaneya T; Yoneyama T
Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
[TBL] [Abstract][Full Text] [Related]
28. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
Segawa N; Inamoto T; Ibuki N; Mizutani Y; Azuma H; Tsuji M; Katsuoka Y
Hinyokika Kiyo; 2010 Jan; 56(1):49-54. PubMed ID: 20104011
[TBL] [Abstract][Full Text] [Related]
29. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
El-Gabry EA; Strup SE; Gomella LG
Tech Urol; 2000 Sep; 6(3):221-2. PubMed ID: 10963494
[TBL] [Abstract][Full Text] [Related]
30. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
31. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
32. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
33. Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.
Shioi K; Sakai N; Yoshida M; Nakamura M
Hinyokika Kiyo; 2005 Mar; 51(3):211-4. PubMed ID: 15852680
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
35. Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer.
Turner J; Chaudhary U
Anticancer Drugs; 2009 Mar; 20(3):215-6. PubMed ID: 19104437
[TBL] [Abstract][Full Text] [Related]
36. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
Ouzaid I; Rouprêt M
Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
[TBL] [Abstract][Full Text] [Related]
37. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy.
Kaufman DS; McDougal WS; Zietman AL; Harisinghani MG; Young RH
N Engl J Med; 2004 Jul; 351(2):171-8. PubMed ID: 15247358
[No Abstract] [Full Text] [Related]
38. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
Lee KC; Bradley DA; Hussain M; Meyer CR; Chenevert TL; Jacobson JA; Johnson TD; Galban CJ; Rehemtulla A; Pienta KJ; Ross BD
Neoplasia; 2007 Dec; 9(12):1003-11. PubMed ID: 18084607
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
40. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
